RIP2 inhibits DOCK8-mediated platelet dense granule release and alleviates experimental myocardial infarction

Jianjun Zhang, Guanxing Pan, Yangyang Liu, Lin Chang, Liang Hu, Zhiyong Qi, Zhiling Zhang, Yan Zhang, Si Zhang, Jianlin Qiao, Xiaodong Xi, Kesheng Dai, Jianzeng Dong, Zhongren DingbioRxiv 2025 · DOI

Abstract

Receptor-interacting protein 2 (RIP2) is an essential mediator of inflammation and innate immunity. While its role in immune cells is well-documented, its function in platelets has remained unknown. This study identifies RIP2 as a critical negative regulator of platelet activation. RIP2 deficiency enhances dense granule secretion and platelet aggregation, leading to accelerated thrombosis and exacerbated myocardial infarction (MI). Mechanistically, phosphorylated RIP2 (p-RIP2) sequesters DOCK8, preventing Cdc42 activation and subsequent granule release. These findings suggest that the RIP2 pathway is a promising target for therapeutic intervention in atherothrombotic diseases.

Introduction

Platelets are vital for hemostasis but can also trigger life-threatening thrombosis, leading to myocardial infarction and stroke. While the pathways that activate platelets are well-mapped, the endogenous "brakes" that prevent over-activation are less understood.

RIP2 is typically associated with signaling downstream of pattern recognition receptors (PRRs) like NOD2. Although platelets express RIP2, its functional significance in platelet biology was previously a mystery. This research investigates how RIP2 influences platelet behavior and how its deficiency contributes to cardiovascular diseases like coronary artery disease (CAD).

Key abbreviations used in the study.

Methods

The researchers employed a multi-disciplinary approach combining genetic mouse models, human clinical samples, and high-resolution molecular biology:

  • Genetic Models: $RIP2^{-/-}$ mice and $ApoE^{-/-}$ mice (a model for atherosclerosis).
  • Platelet Function Assays: Lumi-aggregometry (to measure aggregation and ATP release), flow cytometry (for surface marker expression), and electron microscopy.
  • In Vivo Thrombosis Models: Tail bleeding assays, $FeCl_3$-induced arterial injury, and a mouse model of ischemia/reperfusion (I/R) to simulate a heart attack.
  • Molecular Mechanism: Mass spectrometry and co-immunoprecipitation (Co-IP) were used to identify RIP2 binding partners, specifically looking at the phosphorylation of RIP2 at Serine 176.

Key Insights: The DOCK8-Cdc42 "Brake" Mechanism

The study reveals a novel, PRR-independent signaling pathway in platelets where RIP2 acts as a negative regulator:

  • A Non-Canonical Role: Classically, RIP2 is a pro-inflammatory signal. Here, it acts as a "molecular brake." Surprisingly, this inhibitory effect is independent of its usual partner, NOD2.
  • Sequestration of DOCK8: Upon platelet stimulation, RIP2 becomes phosphorylated (p-RIP2). This p-RIP2 then binds to and sequesters DOCK8 (a guanine nucleotide exchange factor). By "locking up" DOCK8, RIP2 prevents it from activating Cdc42, a small GTPase required for the release of dense granules.
  • Specific to Dense Granules: RIP2 deficiency specifically boosts the release of dense granules (containing ADP and serotonin) but does not affect $\alpha$-granules (measured by P-selectin).

Key Results

  • Enhanced Secretion and Aggregation: $RIP2^{-/-}$ platelets showed significantly higher ATP and serotonin release in response to agonists like thrombin and collagen.
  • Accelerated Thrombosis: $RIP2^{-/-}$ mice had shorter bleeding times and formed occlusive arterial clots much faster than wild-type mice.
  • Worse Heart Attack Outcomes: In the MI model, mice lacking platelet RIP2 suffered from significantly larger infarct sizes (44.1% vs 31.6% of the area at risk) and worse cardiac contractile function.
  • Human Validation: While mRNA levels were similar, RIP2 protein levels were significantly reduced in platelets from CAD patients compared to healthy controls, suggesting a post-translational degradation mechanism in diseased vessels.

Conclusion and Future Work

RIP2 is a critical negative regulator of platelet activation, acting through a novel p-RIP2-DOCK8-Cdc42 axis. Its loss in patients with coronary artery disease may contribute to hyper-reactive platelets and increased thrombotic risk.

Future research is needed to identify the specific proteases responsible for RIP2 degradation in CAD patients and to explore the potential of "RIP2 boosters" as a therapeutic strategy. Ensuring such compounds do not cause systemic immune side effects remains a significant challenge.

Study Highlights

Summary updated

Abstract

Abstract Objective Receptor-interacting protein 2 (RIP2) is an essential mediator of inflammation and innate immunity downstream of pattern recognition receptors (PRRs). Platelets express RIP2, while its role in platelet activation, thrombosis, and myocardial infarction (MI) is unknown. Approach and Results Here we show that RIP2 deficiency enhances platelet dense granule secretion in response to GPIb and GPVI activation; platelet aggregation in whole blood and adhesion under arterial shear are also increased. Consistently, RIP2 inhibitor WEHI-345 potentiates human platelet dense granule secretion and inhibits RIP2 phosphorylation induced by thrombin and collagen. These phenotypes are translated into shorter bleeding time, accelerated FeCl 3 -induced arterial thrombosis. Importantly, platelets from patients with coronary artery disease and mice with atherosclerosis express lower RIP2, and RIP2 deficiency deteriorates MI and cardiac function in a mouse ischemia/reperfusion model. Mechanistically, we found that platelets express dedicator of cytogenesis protein 8 (DOCK8), which is sequestered by phosphorylated RIP2 (p-RIP2), causing inhibition of Cdc42 activation and subsequent dense granule release. Conclusions In conclusion, RIP2 inhibits platelet activation, thrombosis, and ameliorates MI. Our results also suggest that a novel PRR-independent pathway, p-RIP2-DOCK8-Cdc42, negatively regulates platelet activation downstream of GPIb and GPVI. Platelet RIP2 pathway may be promising for therapeutic intervention of atherothrombotic diseases from early atherosclerosis stage to arterial thrombosis and MI. Highlights RIP2 inhibits platelet dense granule release NOD2-independenly via pRIP2-DOCK8-Cdc42. The negative regulation of RIP2 on platelet activation is translated into enhanced thrombosis, exacerbated myocardial infarction (MI). RIP2 pathway booster may be an approach for therapeutic intervention of atherothrombotic diseases.
BibTeX
@misc{zhang2025rip,
  author = {Jianjun Zhang and Guanxing Pan and Yangyang Liu and Lin Chang and Liang Hu and Zhiyong Qi and Zhiling Zhang and Yan Zhang and Si Zhang and Jianlin Qiao and Xiaodong Xi and Kesheng Dai and Jianzeng Dong and Zhongren Ding},
  title = {{RIP2 inhibits DOCK8-mediated platelet dense granule release and alleviates experimental myocardial infarction}},
  year = {2025},
  doi = {10.1101/2025.04.19.649674},
  howpublished = {bioRxiv},
}
Figure